<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36669700</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling.</ArticleTitle><Pagination><StartPage>276</StartPage><EndPage>284</EndPage><MedlinePgn>276-284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virs.2023.01.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1995-820X(23)00006-8</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) poses a serious threat to human health, with scattered outbreaks worldwide. There are several vaccines against a few EV71 strains but no efficient drug for the treatment of EV71 infection. Therefore, it is urgent and of significance to develop anti-EV71 drugs. Here, we found that PLX8394, a RAF inhibitor, possesses high antiviral activity against EV71 in vitro, being superior to the traditional clinical drug ribavirin. Moreover, PLX8394 exhibits broad-spectrum antiviral activity against enteroviruses. Notably, in a suckling mouse model, PLX8394 provided a 70% protection rate for EV71-infected mice, reduced the viral load in liver and heart tissues, and relieved the inflammatory response. A mechanistic study showed that PLX8394 inhibited EV71 by suppressing the RAF/MEK/ERK signaling pathway. Thus, PLX8394 lays a foundation for the development of new drugs against EV71.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Publishing services by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chengyuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guangyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Fuli</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dingyu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China. Electronic address: 2020jy0001@hust.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China. Electronic address: yangqingyu8671@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chaolin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430023, China. Electronic address: 2020jy0003@hust.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000602642">PLX8394</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.12.2</RegistryNumber><NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral agents</Keyword><Keyword MajorTopicYN="N">Enterovirus 71 (EV71)</Keyword><Keyword MajorTopicYN="N">Hand, foot, and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">RAF inhibitor</Keyword><Keyword MajorTopicYN="N">RAF/MEK/ERK signaling Pathway</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36669700</ArticleId><ArticleId IdType="pmc">PMC10176437</ArticleId><ArticleId IdType="doi">10.1016/j.virs.2023.01.006</ArticleId><ArticleId IdType="pii">S1995-820X(23)00006-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abzug M.J. The enteroviruses: problems in need of treatments. J.&#xa0;Infect. 2014;68(Suppl. 1):S108&#x2013;S114.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn J., Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 1994;91:10350&#x2013;10354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45017</ArticleId><ArticleId IdType="pubmed">7937954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Wang Y., Liu Q., Xia J., Long J.E. Prediction of signaling pathways involved in enterovirus 71 infection by algorithm analysis based on miRNA profiles and their target genes. Arch. Virol. 2015;160:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">25287131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogoyevitch M.A., Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol. Mol. Biol. Rev. 2006;70:1061&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698509</ArticleId><ArticleId IdType="pubmed">17158707</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;ceres C.J., Hu Y., C&#xe1;rdenas-Garc&#xed;a S., Wu X., Tan H., Carnaccini S., Gay L.C., Geiger G., Ma C., Zhang Q.Y., Rajao D., Perez D.R., Wang J. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerg. Microb. Infect. 2021;10:1832&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451667</ArticleId><ArticleId IdType="pubmed">34427541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Tsao K.C., Hsia S.H., Shih S.R., Huang C.G., Chan W.K., Hsu K.H., Fang T.Y., Huang Y.C., Lin T.Y. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291:222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722149</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Xie S., Chen C., Choi B.H. Ras sumoylation in cell signaling and transformation. Semin. Cancer Biol. 2021;76:301&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">33812985</ArticleId></ArticleIdList></Reference><Reference><Citation>Flory E., Weber C.K., Chen P., Hoffmeyer A., Jassoy C., Rapp U.R. Plasma membrane-targeted Raf kinase activates NF-kappaB and human immunodeficiency virus type 1 replication in T lymphocytes. J.&#xa0;Virol. 1998;72:2788&#x2013;2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109723</ArticleId><ArticleId IdType="pubmed">9525598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemnejad-Berenji M., Pashapour S. SARS-CoV-2 and the possible role of Raf/MEK/ERK pathway in viral survival: is this a potential therapeutic strategy for COVID-19? Pharmacology. 2021;106:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573895</ArticleId><ArticleId IdType="pubmed">33011728</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Chen Z., Zheng K., Li X., Kong J., Duan X., Xiao X., Guo B., Luan R., Long L. Epidemiology of hand, foot, and mouth disease before and after the introduction of enterovirus 71 vaccines in chengdu, China, 2009-2018. Pediatr. Infect. Dis. J. 2020;39:969&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32433221</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber M., Watson K.A., Selinka H.C., Carthy C.M., Klingel K., Mcmanus B.M., Kandolf R. Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication. J.&#xa0;Virol. 1999;73:3587&#x2013;3594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104132</ArticleId><ArticleId IdType="pubmed">10196249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X., Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med. Res. Rev. 2020;40:1519&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228277</ArticleId><ArticleId IdType="pubmed">32060956</ArticleId></ArticleIdList></Reference><Reference><Citation>Khojasteh Poor F., Keivan M., Ramazii M., Ghaedrahmati F., Anbiyaiee A., Panahandeh S., Khoshnam S.E., Farzaneh M. Mini review: the FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Dis. 2021;40:51&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">33896802</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong S.Y., Ong B.K., Chu J.J. The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352056</ArticleId><ArticleId IdType="pubmed">25747578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as&#xa0;an anti-viral approach against influenza virus infections. Biol. Chem. 2011;392:837&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">21823902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S., Planz O., Pleschka S., Wolff T. Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol. Med. 2003;9:46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S., Wolff T., Ehrhardt C., Wurzer W.J., Reinhardt J., Planz O., Pleschka S. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 2004;561:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata K., Kawaguchi A., Naito T. Host factors for replication and transcription of the influenza virus genome. Rev. Med. Virol. 2008;18:247&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">18383427</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Z., Wang H., Zhao Z., Chen X., Huan C., Zhang W. Chemokine PF4 inhibits EV71 and CA16 infections at the entry stage. J.&#xa0;Virol. 2022;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9175630</ArticleId><ArticleId IdType="pubmed">35579435</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H., Shi M., Zhang L., Li Y., Sun J., Zhang L., Wang X., Xu X., Zhang X., Mao Y., Ji Y., Jiang J., Shi W. Activation of JNK1/2 and p38 MAPK signaling pathways promotes enterovirus 71 infection in immature dendritic cells. BMC Microbiol. 2014;14:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057572</ArticleId><ArticleId IdType="pubmed">24906853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 2001;3:301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated&#xa0;from patients with disease of the central nervous system. J.&#xa0;Infect. Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W.H., Hsieh H.L., Yang C.M. Enterovirus 71 induces COX-2 expression via MAPKs, NF-kappaB, and AP-1 in SK-N-SH cells: role of PGE(2) in viral replication. Cell. Signal. 2010;22:234&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">19800403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm. Sin. B. 2022;12:1542&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen T., Xu W., Liang L., Li J., Ding X., Chen X., Hu J., Lv A., Li X. Clinical efficacy of andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease (HFMD) is dependent upon inhibition of neutrophil activation. Phytother Res. 2015;29:1161&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">25960284</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N., Yang J., Zheng B., Zhang Y., Cao Y., Huan C., Wang S., Chang J., Zhang W. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J.&#xa0;Virol. 2020;94:e00204&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163137</ArticleId><ArticleId IdType="pubmed">32075935</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Zhang Q., Zhang X., You L., Wang W., Liu W., Han Y., Ma C., Xu W., Chen J., Yang H., Wan P., Zhou Y., Liu Y., Wu K., Yang Z., Wu J. HoxA10 facilitates SHP-1-Catalyzed dephosphorylation of p38 MAPK/STAT3 to Repress hepatitis B virus replication by a feedback regulatory mechanism. J.&#xa0;Virol. 2019;93:e01607&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430538</ArticleId><ArticleId IdType="pubmed">30674631</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., De Stanchina E., Hyman D.M., Bollag G., Rosen N. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat. Med. 2019;25:284&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404779</ArticleId><ArticleId IdType="pubmed">30559419</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee P.T.I., Laa Poh C. Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development. Virology. 2017;506:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">28384566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E.J., Shin Y.J., Kim J.H., Kim T.G., Chang S.Y. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 2017;6:4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin R., Liu X., Bi Y., Xie G., Zhang P., Meng X., Ai L., Xu R., Sun Y., Stoeger T., Ding Z. Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication. J.&#xa0;Gen. Virol. 2015;96:2579&#x2013;2586.</Citation><ArticleIdList><ArticleId IdType="pubmed">26297355</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C.C., Lau S.K., Woo P.C., Yuen K.Y. Human enterovirus 71 epidemics: what's next? Emerg. Health Threats J. 2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Chen X., Shi Y., Zhou B., Du C., Liu Y., Han S., Yin J., Peng B., He X., Liu W. miR-27a suppresses EV71 replication by directly targeting EGFR. Virus Gene. 2014;49:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wei M., Jin P., Li J., Zhu F. An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial. Hum. Vaccines Immunother. 2021;17:2101&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189103</ArticleId><ArticleId IdType="pubmed">33529093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>